Six million euros for Neuronation
Impact Partners invests in Synaptikon, the company behind the health app Neuronation. The start-up also wants to help long-Covid patients in the future.
The French venture capitalist Impact Partners is investing in the German healthtech Synaptikon. The investment amounts to six million euros, as the VC announced. This is Impact Partners' first financing in Germany.
Synaptikon is behind the Neuronation app, a service designed to help people train their cognitive skills. The app is available in nine languages and Synaptikon claims to have already reached 20 million users. For the original development, the start-up cooperated with the Free University of Berlin, and there are now further collaborations with various universities and clinics. Synaptikon is currently working with Charité Berlin, Cologne University Hospital and Jena University Hospital to test whether Neuronation is suitable for treating Long Covid patients.
"We believe that cognitive impairment is one of the biggest problems we face in our ageing society.
we have in our ageing society. Post-Covid-related cognitive disorders
are accelerating this development, and we want to play our part in solving it," says Jakob Futorjanski, who founded the company together with Rojahn Ahmadi in 2011. Synaptikon now wants to use the newly raised capital to strengthen the research behind its own product.
Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
